OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kishtagari on the Impact of Momelotinib on the Management of Anemic Myelofibrosis

May 16th 2024

Ashwin Kishtagari, MD, discusses how momelotinib addresses unmet needs in the management of anemic myelofibrosis following disease progression on ruxolitinib.

Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDS

May 16th 2024

Somedeb Ball, MBBS, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes.

Dr Nye on Paradigm Shifts in the Management of HR+ Breast Cancer

May 16th 2024

Lauren E. Nye, MD, discusses how the expansion of targeted therapies in metastatic hormone receptor–positive breast cancer has shifted management approaches.

Dr Rosenberg on Efforts to Enhance Urothelial Cancer Treatment

May 15th 2024

Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.

Dr Lou on the Predictive and Prognostic Utility of Tumor Stroma Proportion in Ovarian Cancer

May 15th 2024

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.

Dr Koff on Toxicities Associated With Pirtobrutinib in MCL

May 15th 2024

Jean L. Koff, MD, MS, discusses the toxicities associated with pirtobrutinib in the BRUIN trial for mantle cell lymphoma.

Dr Garje on Emerging Biomarkers in mCRPC

May 15th 2024

Rohan Garje, MD, discusses emerging biomarkers in metastatic castration-resistant prostate cancer and where the treatment field is headed.

Dr Tripathy on the Treatment of HER2+ Breast Cancer

May 15th 2024

Debu Tripathy, MD, discusses the current state of HER2-positive breast cancer treatment.

Dr Garmezy on Future Therapeutic Prospects for RCC

May 15th 2024

Meta: Benjamin Garmezy, MD discusses future therapeutic prospects for patients with variant renal cell carcinoma (RCC)

Dr Townsend on Understanding Prostate Cancer and the Utility of Genomic Sequencing

May 15th 2024

Jeffrey P. Townsend, PhD, discusses advancements in the understanding of prostate cancer care through the utility of genomic sequencing.

Dr Iglesia on Unmet Needs in Second-Line Therapy Selection in HCC

May 14th 2024

Michael Iglesia, MD, PhD, discusses uncertainties surrounding the selection of second-line treatment approaches in hepatocellular carcinoma.

Dr Koff on the Safety Profile of Pirtobrutinib in Pretreated CLL/SLL

May 14th 2024

Jean L. Koff, MD, MS, discusses the safety profile of pirtobrutinib in pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Garje on the Utility of Lu 177 Vipivotide Tetraxetan in mCRPC

May 14th 2024

Rohan Garje, MD, discusses the utility of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Dr Chen on the Evolution of Novel Therapies in Breast Cancer

May 14th 2024

Dr Jagannath on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

May 14th 2024

Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma.

Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCL

May 14th 2024

Lori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.

Dr Ignatz-Hoover on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

May 14th 2024

James Ignatz-Hoover, MD, PhD discusses sequencing CAR T cell therapies and bispecific agents in treating pretreated patients with multiple myeloma.

Dr Liu on the Rationale for Targeting Wee1 in Ovarian Cancer

May 13th 2024

Joyce F. Liu, MD, MPH, discusses the role of Wee1 in cell cycle regulation and the rationale for targeting this protein in ovarian cancer.

Dr Pederson on Novel Therapies for the Management of Targetable mCRC

May 13th 2024

Katrina S. Pedersen, MD, MS, discusses key updates in the therapeutic landscape for patients with molecularly targetable metastatic colorectal cancer.

Dr Tripathy on Real-World HER2 Testing and CDK4/6 Inhibitor Use in HER2+ Breast Cancer

May 13th 2024

Debu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.